Gilead Sciences has refiled for FDA approval of its HIV capsid inhibitor lenacapavir – which only needs to be dosed every six months – after the drug was rejected by the regulator in February.
BMO Capital Markets analyst Evan Seigerman in a note to investors called Gilead’s third-quarter performance “consistent” and ...
Despite a robust HIV portfolio and growing oncology sales, Gilead struggles to diversify revenue streams significantly. Learn ...
Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...
Gilead (GILD) announced the upcoming presentation of HIV research findings at the International Congress on Drug Therapy in HIV Infection, ...
Lenacapavir is being evaluated as a potential long-acting option in multiple ongoing and planned early and late-stage clinical studies in Gilead’s HIV prevention and treatment research program.
Data from both studies showcased the superiority of twice-yearly injectable, lenacapavir, compared to once-daily oral Truvada and background HIV incidence rates, prompting Gilead to unblind the ...
Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of HIV research findings at the International ...
Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...
He said Gilead plans to file before the end of this year for U.S. regulatory approval of lenacapavir, a twice-yearly ...
Gilead Sciences posted robust revenue and EPS growth, exceeding expectations, and management raised full-year guidance.